As of Sept. 4, there was an overall response rate of 80% among the 15 patients enrolled so far with PD-L1-high tumorsPD-L1-high tumors who received a domvanalimab-containing regimen, Gilead reported. This dropped to 46% among the 24 patients with PD-L1-low tumorsPD-L1-low tumors. There were two confirmed complete responses in the trial at that point.
The progression-free survival (PFS) rate was 93% among patients in the PD-L1-high group and 68% among the low cohort, Gilead added. Median PFS was not reached, and the Big Pharma is expecting to report mature data on that metric in the second half of next year.
FC receptors are found on the cell surface and contribute to the protective functions of the immune system by binding to antibodies that are attached to infected cells or invading pathogens. TIGITs are broadly split into those that have an FC receptor function—such as Roche’s tiragolumab —and those that have mutated out the receptor function, like domvanalimab.
“These data add to the growing body of evidence that domvanalimab, an FC-silent anti-TIGIT antibody, has a differentiated safety and tolerability profile relative to published data from studies with FC-enabled anti-TIGIT antibodies,” Gilead said in the postmarket release yesterday.
“These early data are encouraging and indicate the potential for the anti-TIGIT, domvanalimab-based therapy to improve upon anti-PD-1 and chemotherapy in this setting, with a similar safety profile to anti-PD-1 and chemotherapy,” said Memorial Sloan Kettering Cancer CenterCancer Center’s Yelena Janjigian, M.D., a principal investigator for study, in the release.
While still early days, Gilead and Arcus’ readout marks another promising clinical development for a once-hyped class of potential medicines that was knocked off track by a pair of phase 3 failures for Roche’s TIGIT tiragolumabTIGIT tiragolumab in lung cancer last year.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.